On November 11, Regeneron Pharmaceuticals fell 3.46% in Pre-Market Trading to $884.41 per share, with turnover of $3.4917 million.
The latest market-moving context points to a pullback after the company’s recently disclosed early clinical data for its liver-targeted siRNA candidate CIDEBsiRNA had lifted sentiment and supported gains in the prior session.
The company reported that a single subcutaneous dose reduced liver fat by 58% to 80% at week 36 with a dose-dependent effect, versus a 2.9% decline in the placebo group. In addition, 93% of participants achieved at least a 30% reduction in liver fat, while ALT and AST liver injury markers continued to improve. Those data were presented recently and had already helped drive the stock higher, making the current pre-market weakness more consistent with short-term retracement after a news-led advance.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments